Advertisement

Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells

Published:January 19, 2017DOI:https://doi.org/10.1016/j.ygyno.2017.01.015

      Highlights

      • A single tumor contains cells representing all defined molecular classifications.
      • Molecular classification based on sequencing of bulk tumor samples is problematic.
      • Single cell sequencing can identify rare cells expressing stem cell markers.

      Abstract

      Objectives

      The purpose of this study was to determine the level of heterogeneity in high grade serous ovarian cancer (HGSOC) by analyzing RNA expression in single epithelial and cancer associated stromal cells. In addition, we explored the possibility of identifying subgroups based on pathway activation and pre-defined signatures from cancer stem cells and chemo-resistant cells.

      Methods

      A fresh, HGSOC tumor specimen derived from ovary was enzymatically digested and depleted of immune infiltrating cells. RNA sequencing was performed on 92 single cells and 66 of these single cell datasets passed quality control checks. Sequences were analyzed using multiple bioinformatics tools, including clustering, principle components analysis, and geneset enrichment analysis to identify subgroups and activated pathways. Immunohistochemistry for ovarian cancer, stem cell and stromal markers was performed on adjacent tumor sections.

      Results

      Analysis of the gene expression patterns identified two major subsets of cells characterized by epithelial and stromal gene expression patterns. The epithelial group was characterized by proliferative genes including genes associated with oxidative phosphorylation and MYC activity, while the stromal group was characterized by increased expression of extracellular matrix (ECM) genes and genes associated with epithelial-to-mesenchymal transition (EMT). Neither group expressed a signature correlating with published chemo-resistant gene signatures, but many cells, predominantly in the stromal subgroup, expressed markers associated with cancer stem cells.

      Conclusions

      Single cell sequencing provides a means of identifying subpopulations of cancer cells within a single patient. Single cell sequence analysis may prove to be critical for understanding the etiology, progression and drug resistance in ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Patel A.P.
        • Tirosh I.
        • Trombetta J.J.
        • Shalek A.K.
        • Gillespie S.M.
        • Wakimoto H.
        • et al.
        Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.
        Science. 2014; 344: 1396-1401
        • Cancer Genome Atlas Research Network
        Integrated genomic analyses of ovarian carcinoma.
        Nature. 2011; 474: 609-615
        • Konecny G.E.
        • Wang C.
        • Hamidi H.
        • Winterhoff B.
        • Kalli K.R.
        • Dering J.
        • et al.
        Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
        J. Natl. Cancer Inst. 2014; 106
        • Calon A.
        • Lonardo E.
        • Berenguer-Llergo A.
        • Espinet E.
        • Hernando-Momblona X.
        • Iglesias M.
        • et al.
        Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.
        Nat. Genet. 2015; 47: 320-329
        • Isella C.
        • Terrasi A.
        • Bellomo S.E.
        • Petti C.
        • Galatola G.
        • Muratore A.
        • et al.
        Stromal contribution to the colorectal cancer transcriptome.
        Nat. Genet. 2015; 47: 312-319
        • Langmead B.
        • Trapnell C.
        • Pop M.
        • Salzberg S.L.
        Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
        Genome Biol. 2009; 10: R25
        • Li B.
        • Dewey C.N.
        RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.
        BMC Bioinform. 2011; 12: 323
        • de Hoon M.J.
        • Imoto S.
        • Nolan J.
        • Miyano S.
        Open source clustering software.
        Bioinformatics. 2004; 20: 1453-1454
        • Page R.D.
        TreeView: an application to display phylogenetic trees on personal computers.
        Comput. Appl. Biosci. 1996; 12: 357-358
        • Subramanian A.
        • Tamayo P.
        • Mootha V.K.
        • Mukherjee S.
        • Ebert B.L.
        • Gillette M.A.
        • et al.
        Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
        Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 15545-15550
        • Mootha V.K.
        • Lindgren C.M.
        • Eriksson K.F.
        • Subramanian A.
        • Sihag S.
        • Lehar J.
        • et al.
        PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.
        Nat. Genet. 2003; 34: 267-273
        • Whitfield M.L.
        • Sherlock G.
        • Saldanha A.J.
        • Murray J.I.
        • Ball C.A.
        • Alexander K.E.
        • et al.
        Identification of genes periodically expressed in the human cell cycle and their expression in tumors.
        Mol. Biol. Cell. 2002; 13: 1977-2000
        • Lamouille S.
        • Xu J.
        • Derynck R.
        Molecular mechanisms of epithelial-mesenchymal transition.
        Nat. Rev. Mol. Cell Biol. 2014; 15: 178-196
        • Liberzon A.
        • Subramanian A.
        • Pinchback R.
        • Thorvaldsdottir H.
        • Tamayo P.
        • Mesirov J.P.
        Molecular signatures database (MSigDB) 3.0.
        Bioinformatics. 2011; 27: 1739-1740
        • Tothill R.W.
        • Tinker A.V.
        • George J.
        • Brown R.
        • Fox S.B.
        • Lade S.
        • et al.
        Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
        Clin. Cancer Res. 2008; 14: 5198-5208
        • Yoshihara K.
        • Shahmoradgoli M.
        • Martinez E.
        • Vegesna R.
        • Kim H.
        • Torres-Garcia W.
        • et al.
        Inferring tumour purity and stromal and immune cell admixture from expression data.
        Nat. Commun. 2013; 4: 2612
        • Zhang S.
        • Balch C.
        • Chan M.W.
        • Lai H.C.
        • Matei D.
        • Schilder J.M.
        • et al.
        Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
        Cancer Res. 2008; 68: 4311-4320
        • Curley M.D.
        • Therrien V.A.
        • Cummings C.L.
        • Sergent P.A.
        • Koulouris C.R.
        • Friel A.M.
        • et al.
        CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
        Stem Cells. 2009; 27: 2875-2883
        • Silva I.A.
        • Bai S.
        • McLean K.
        • Yang K.
        • Griffith K.
        • Thomas D.
        • et al.
        Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
        Cancer Res. 2011; 71: 3991-4001
        • Eisenberg E.
        • Levanon E.Y.
        Human housekeeping genes, revisited.
        Trends Genet. 2013; 29: 569-574
        • Sherman-Baust C.A.
        • Becker K.G.
        • Wood Iii W.H.
        • Zhang Y.
        • Morin P.J.
        Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin.
        J Ovarian Res. 2011; 4: 21
        • Polyak K.
        • Weinberg R.A.
        Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
        Nat. Rev. Cancer. 2009; 9: 265-273
        • Cheng L.
        • Lu W.
        • Kulkarni B.
        • Pejovic T.
        • Yan X.
        • Chiang J.H.
        • et al.
        Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies.
        Gynecol. Oncol. 2010; 117: 159-169
        • Patch A.M.
        • Christie E.L.
        • Etemadmoghadam D.
        • Garsed D.W.
        • George J.
        • Fereday S.
        • et al.
        Whole-genome characterization of chemoresistant ovarian cancer.
        Nature. 2015; 521: 489-494
        • Steffensen K.D.
        • Alvero A.B.
        • Yang Y.
        • Waldstrom M.
        • Hui P.
        • Holmberg J.C.
        • et al.
        Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.
        J Oncol. 2011; 2011: 620523
        • Kryczek I.
        • Liu S.
        • Roh M.
        • Vatan L.
        • Szeliga W.
        • Wei S.
        • et al.
        Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
        Int. J. Cancer. 2012; 130: 29-39
        • Bellone S.
        • Siegel E.R.
        • Cocco E.
        • Cargnelutti M.
        • Silasi D.A.
        • Azodi M.
        • et al.
        Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
        Int. J. Gynecol. Cancer. 2009; 19: 860-866
        • Alvero A.B.
        • Chen R.
        • Fu H.H.
        • Montagna M.
        • Schwartz P.E.
        • Rutherford T.
        • et al.
        Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
        Cell Cycle. 2009; 8: 158-166
        • Landen Jr., C.N.
        • Goodman B.
        • Katre A.A.
        • Steg A.D.
        • Nick A.M.
        • Stone R.L.
        • et al.
        Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
        Mol. Cancer Ther. 2010; 9: 3186-3199
        • Ye X.
        • Weinberg R.A.
        Epithelial-mesenchymal plasticity: a central regulator of cancer progression.
        Trends Cell Biol. 2015; 25: 675-686
        • Shah M.M.
        • Landen C.N.
        Ovarian cancer stem cells: are they real and why are they important?.
        Gynecol. Oncol. 2014; 132: 483-489
        • Burgos-Ojeda D.
        • Rueda B.R.
        • Buckanovich R.J.
        Ovarian cancer stem cell markers: prognostic and therapeutic implications.
        Cancer Lett. 2012;
        • Bast Jr., R.C.
        • Hennessy B.
        • Mills G.B.
        The biology of ovarian cancer: new opportunities for translation.
        Nat. Rev. Cancer. 2009; 9: 415-428
        • Quintana E.
        • Shackleton M.
        • Sabel M.S.
        • Fullen D.R.
        • Johnson T.M.
        • Morrison S.J.
        Efficient tumour formation by single human melanoma cells.
        Nature. 2008; 456: 593-598
        • Verhaak R.G.
        • Tamayo P.
        • Yang J.Y.
        • Hubbard D.
        • Zhang H.
        • Creighton C.J.
        • et al.
        Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
        J. Clin. Invest. 2013; 123: 517-525

      Linked Article